Midatech is an international specialty pharmaceutical company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need.

Midatech is commercialising oncology treatment and supportive care products via its US Commercial Organisation, Midatech Pharma US. In Europe, Midatech is advancing a pipeline of novel clinical and pre-clinical product candidates based on its proprietary drug conjugate and sustained release delivery platforms with a clear focus on the key therapeutic areas of Cancer, Endocrine Disorders such as Diabetes, and Immunotherapy for autoimmune diseases.

Midatech’s strategy is to expand it US commercial arm as well as develop its products in-house in rare cancers and with partners in other indications, and to accelerate growth of its business through strategic acquisition of complementary products and technologies.

Midatech 2016 Annual General Meeting is to be held on Wednesday 11 May 2016 – Click here to view AGM notice
Download Midatech 2015 Final Results Presentation Click here
Latest News...
May 18, 2016
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), today announces an update on its clinical pipeline developments.... Read More
May 11, 2016
Midatech Pharma (AIM: MTPH; Nasdaq: MTP), today will host its Annual General Meeting at Panmure Gordon... Read More
Apr 26, 2016
~ Release profile of Midatech’s Q-Octreotide compared favourably with the reference product and current... Read More



Privacy and cookie policy


  © Copyright 2014 Midatech